A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Sparta

Protocol Number
D48488C001 Concerto

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD

Protocol Number
Serono Javelin

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) vs capecitabine in the treatment of GNPNMC Over-expressing, Triple Negative Breast Cancer

Type of Cancer
Breast Oncology

Site
Freehold, Howell, Sparta

Protocol Number
CDX011-04

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma

Type of Cancer
Pancreatic

Site
East Brunswick, Freehold, Howell, Little Silver, Marmora, Mount Holly, Sparta

Sponsor
Boston Biomedical Inc

Protocol Number
CanStem111P

To Learn More Call
201-510-0910

Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant

Type of Cancer
Multiple Myeloma

Site
East Brunswick, Freehold, Howell, Little Silver, Sparta

Sponsor
MERCK

Protocol Number
MERCK-3475-185

To Learn More Call
201-510-0910

A Phase III open-label, multicenter trial of maintenancetherapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

Type of Cancer
Gastrointestinal

Site
East Brunswick, Freehold, Howell, Mount Holly, Sparta

Sponsor
EMD Serono

Protocol Number
JAVELIN

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Bevacizumab Versus Sunitinib In Patients With Untreated Advanced Renal Cell Carcinoma

Type of Cancer
Unknown Primary

Site
Freehold, Sparta

Protocol Number
Genentech WO29637 Renal Cell

Cancer Diagnosis
Renal Cancer

To Learn More Call
201-510-0910

A Phase 3B study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide Single agent maintenance versus rituxumab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma

Type of Cancer
Lymphoma

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Celgene

Protocol Number
CC-5013-NHL-008 MAGNIFY

To Learn More Call
201-510-0910

A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a suspected de